{"doi":"10.7554/elife.54854","title":"Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells","abstract":"Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. Treatment of xenograft tumors resulted in PD-L1-dependent tumor growth inhibition. PD-L1 CAR haNKs reduced levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood from patients with head and neck cancer. The clinical study of PD-L1 CAR haNKs is warranted.","journal":"eLife","year":2020,"id":60977,"datarank":2.111577521842411,"base_score":4.0943445622221,"endowment":4.0943445622221,"self_citation_contribution":0.6141516843333151,"citation_network_contribution":1.497425837509096,"self_endowment_contribution":0.6141516843333151,"citer_contribution":1.497425837509096,"corpus_percentile":null,"corpus_rank":null,"citation_count":59,"citer_count":44,"citers_with_citation_signal":41,"citers_with_endowment":41,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9561,"is_data_producer":true,"deposit_databanks":{"Dryad":["10.5061/dryad.sf7m0cg3k"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":322331,"name":"Sarah Greene","orcid":"0000-0001-5223-3525","position":1,"is_corresponding":false},{"id":322332,"name":"Jay Friedman","orcid":"0009-0008-3063-3606","position":2,"is_corresponding":false},{"id":322333,"name":"Paúl E. Clavijo","orcid":"0000-0003-2279-2515","position":3,"is_corresponding":false},{"id":322334,"name":"Carter Van Waes","orcid":"0000-0002-9599-5113","position":4,"is_corresponding":false},{"id":322335,"name":"Kellsye P. Fabian","orcid":"0000-0002-0273-5647","position":5,"is_corresponding":false},{"id":242494,"name":"Michelle R. Padget","orcid":"0000-0003-4922-1042","position":6,"is_corresponding":false},{"id":256066,"name":"Houssein Abdul Sater","orcid":"0000-0003-1975-3726","position":7,"is_corresponding":false},{"id":322336,"name":"John H Lee","orcid":"0000-0002-5674-7969","position":8,"is_corresponding":false},{"id":321139,"name":"Patrick Soon‐Shiong","orcid":"0000-0002-4682-8298","position":9,"is_corresponding":false},{"id":239942,"name":"James L. Gulley","orcid":"0000-0002-6569-2912","position":10,"is_corresponding":false},{"id":239943,"name":"Jeffrey Schlom","orcid":"0000-0001-7932-4072","position":11,"is_corresponding":false},{"id":242498,"name":"James W. Hodge","orcid":"0000-0001-5282-3154","position":12,"is_corresponding":false},{"id":260382,"name":"Clint Allen","orcid":"0000-0001-6586-5804","position":13,"is_corresponding":false},{"id":322330,"name":"Yvette Robbins","orcid":"0000-0003-0940-3941","position":0,"is_corresponding":true}],"reference_count":49,"raw_metadata":null,"created_at":"2026-07-18T21:09:27.985420Z","pmid":"32633234","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}